All data pertaining to Covid vaccine trials should be made public: PMSF

Progressive Medicos and Scientists Forum said the Clinical Trial (PMSF) Phase 3 data should be evaluated in a transparent manner as and when available for India for both vaccines

Bengaluru, vaccination, vaccine
The decision to grant Emergency Use Authorization (EUA) may be revisited once the Phase 3 trials are completed, PMSF said
Press Trust of India New Delhi
1 min read Last Updated : Jan 17 2021 | 10:07 PM IST

A national association of doctors and scientists has demanded that all data pertaining to Covid-19 vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccination.

In a statement issued on Sunday, the Progressive Medicos and Scientists Forum said the Clinical Trial (PMSF) Phase 3 data should be evaluated in a transparent manner as and when available for India for both vaccines and the decision to grant Emergency Use Authorization (EUA) may be revisited once the Phase 3 trials are completed.

They demanded that all data pertaining to the vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccines for themselves and for their larger communities.

"All healthcare workers should have an option for opting out without any fear, coercion or any other adverse impact on them, including linking vaccination status to air travel restrictions," it said.

The body further demanded that the continuation or eligibility for working as healthcare should not have any precondition of Covid-19 vaccination, as is being done in a few countries.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccineclinical trialsBharat BiotechSerum Institute of India

Next Story